Crescent Biopharma, Inc. (CBIO) Stock Price & Analysis
Crescent Biopharma, Inc. (CBIO) rose 4.17% to USD 18 as of June 10, 2026 at 04:59 UTC, according to Nexqual real-time market data.
CBIO last closed at USD 17.28; the session ranged USD 17.25–18.23 on volume of 126,104 shares. Market capitalization is $496.35M, with a 52-week range of USD 8.72–27.41 (NCM). Source: Nexqual, June 10, 2026 at 04:59 UTC.
Key Statistics (as of June 10, 2026 at 04:59 UTC)
| Price | USD 18 |
|---|---|
| Change | ▲ 4.17% (up) |
| Previous Close | USD 17.28 |
| Open | USD 17.38 |
| Day Range | USD 17.25 – 18.23 |
| 52-Week Range | USD 8.72 – 27.41 |
| Volume | 126,104 shares |
| Market Cap | $496.35M |
| Exchange | NCM |
Technical Analysis (CBIO)
Nexqual's technical model rates CBIO "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 04:59 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 37.4 (neutral) |
| vs SMA50 | Below (USD 19.85) |
| MACD | -0.39 (negative) |
Analyst Ratings (CBIO)
Wall Street analysts rate CBIO "Strong Buy" based on 6 analysts, with a mean price target of USD 31.67 (range USD 27–35), per Nexqual as of June 10, 2026 at 04:59 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 31.67 |
| High Target | USD 35 |
| Low Target | USD 27 |
| Buy / Hold / Sell | 8 / 1 / 0 |
Earnings (CBIO)
| EPS Estimate | USD -0.64 |
|---|---|
| Revenue Estimate | $357,140 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.7 vs est -0.79 ▲ beat |
| 2025-12-31 | USD -4.92 vs est -2.82 ▼ miss |
| 2025-09-30 | USD -1.37 vs est -1.39 ▲ beat |
| 2025-06-30 | USD -3.72 vs est -3.68 ▼ miss |
Source: Nexqual, June 10, 2026 at 04:59 UTC.
Financials & Fundamentals (CBIO)
| Total Revenue | $11.88M |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -2380.08% |
| Profit Margin | +0.00% |
| Debt / Equity | 0.84 |
| Current Ratio | 13.78 |
| Total Cash | $189.16M |
| Total Debt | $1.54M |
Source: Nexqual, June 10, 2026 at 04:59 UTC.
Financial Health Score (CBIO)
Nexqual rates Crescent Biopharma, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 04:59 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $189M cash vs $2M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$70M |
| Efficiency | Mixed — No data |
Ownership (CBIO)
| Insider Ownership | +6.16% |
|---|---|
| Institutional Ownership | +96.25% |
| Shares Outstanding | 27.57M |
| Float | 14.60M |
| Short % of Float | +26.98% |
Source: Nexqual, June 10, 2026 at 04:59 UTC.
Leadership (CBIO)
Crescent Biopharma, Inc. is led by Joshua T. Brumm (age 47), CEO & Director, per Nexqual as of June 10, 2026 at 04:59 UTC.
| CEO & Director | Joshua T. Brumm (age 47) |
|---|---|
| President & COO | Jonathan McNeill (age 40) |
| Chief Financial Officer | Richard William Scalzo (age 39) |
| Senior Vice President of Technical Operations | Wenjie Cheng |
| Chief Scientific Officer | Jan Pinkas (age 56) |
Major Backers & Investors (CBIO)
Notable institutional backers of Crescent Biopharma, Inc. include FMR, LLC, BVF Inc., Fairmount Funds Management LLC, according to Nexqual as of June 10, 2026 at 04:59 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.99% |
| BVF Inc. | 9.97% |
| Fairmount Funds Management LLC | 9.97% |
| Venrock Adviser, LLC | 7.74% |
| FCPM III Services B.V. | 6.09% |
| Balyasny Asset Management LP | 5.48% |
| Vestal Point Capital, LP | 5.44% |
| Opaleye Management Inc. | 4.76% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.74% |
Source: Nexqual, June 10, 2026 at 04:59 UTC.
From Crescent Biopharma, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Partnerships
- We recently announced a partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun"), a leading Chinese biotech company with commercially approved ADCs, to acquire exclusive rights to SKB105 (also referred to as CR-003), an integrin beta-6 ("ITGB6")-directed ADC, outside of mainland China, Hong Kong, Macau, and Taiwan (collectively, "Greater China").
- The potential to combine CR-001 with ADCs is a key element of our partnership with Kelun.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BNTC | Benitec Biopharma Inc. | USD 10.81 | ▲ 2.46% |
| AKTX | Akari Therapeutics Plc | USD 15 | ▼ 0.46% |
| PULM | Pulmatrix, Inc. | USD 1.38 | ▲ 3.76% |
| IDXG | Interpace Biosciences, Inc. | USD 1.74 | ▲ 4.19% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:59 UTC. This page is informational and not investment advice.